USA flag logo/image

An Official Website of the United States Government

Selective Fyn kinase inhibitors for treatment of metabolic disease

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
 Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43DK093387 		Solicitation Year:
2011 		Solicitation Topic Code:
NIDDK 		Solicitation Number:
PA10-050
Small Business Information
ZEN-BIO, INC.
P.O. BOX 13888 3200 CHAPEL HILL-NELSON BLVD. RTP, NC 27709-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Selective Fyn kinase inhibitors for treatment of metabolic disease
Agency: HHS
Contract: 1R43DK093387-01
Award Amount: $350,681.00
 

Abstract:

DESCRIPTION (provided by applicant): Metabolic diseases such as type 2 diabetes (T2D), obesity and their related co-morbidities have reached epidemic proportions worldwide. While progress continues to be made into the molecular mechanisms involved in bothobesity and T2D, the identification and development of safe, efficacious therapeutic modalities is significantly limited. There is an urgent need for innovative medicines to combat both obesity and diabetes. Recent data along with our preliminary data strongly suggest that pharmacological intervention of Fyn kinase provides an excellent target and novel approach for the discovery of new drugs to treat metabolic disease. In preliminary high throughput screens we have identified a promising selective inhibitor of Fyn kinase. This proposal describes an approach for further development and identification of additional analogs of our lead compound. This will include SAR based on novel chemistries, characterization in human cell-based assays for glucose and fattyacid metabolism as well as biochemical assays centered on potential mechanism of action. PUBLIC HEALTH RELEVANCE: Metabolic diseases such as type 2 diabetes, obesity and their related co-morbidities have reached epidemic proportions worldwide. Thereis an urgent need for innovative medicines to combat both obesity and diabetes. This proposal focuses on further development and identification of lead small molecule drug for the treatment of metabolic disease.

Principal Investigator:

Bentley Cheatham
919-547-0692
bentley@zen-bio.com

Business Contact:

Benjamin Buehrer
919-547-0692
ben@zenbio.com
Small Business Information at Submission:

ZEN-BIO, INC.
P.O. BOX 13888 3200 CHAPEL HILL-NELSON BLVD. RTP, NC -

EIN/Tax ID: 156194016
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No